Pulmonary hypertension and β-thalassemia major: Report of a case, its treatment, and a review of the literature

American Journal of Hematology

Volumn 81, Issue 6, 2006, Pages 443-447

  Tam, Denise H ^a   Farber, Harrison W ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

thalassemia major; Epoprostenol; Pulmonary hypertension

Indexed keywords

DEFEROXAMINE; PROSTACYCLIN;

ADULT; CASE REPORT; DIABETES MELLITUS; DYSPNEA; HEART CATHETERIZATION; HEMODYNAMICS; HEMOSIDEROSIS; HEPATITIS C; HUMAN; LUNG FUNCTION TEST; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SPLENECTOMY; THALASSEMIA MAJOR; TRANSTHORACIC ECHOCARDIOGRAPHY;

ADULT; ANTIHYPERTENSIVE AGENTS; BETA-THALASSEMIA; DEFEROXAMINE; DYSPNEA; EPOPROSTENOL; HEMOSIDEROSIS; HEPATITIS C; HUMANS; HYPERTENSION, PULMONARY; MALE; RECOVERY OF FUNCTION; REMISSION INDUCTION; SIDEROPHORES;

EID: 33646896781     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20603     Document Type: Review

References (47)

1. Zurlo MG, De Stefano P, Borgna-Pignatti C, et al. Survival and causes of death in thalassaemia major. Lancet 1989;8653:27-30.
2. Leon MB, Borer JS, Bacharach SL, et al. Detection of early cardiac dysfunction in patients with severe β-thalassemia and chronic iron overload. N Engl J Med 1979;301:1143-1148.
3. Kremastinos DT, Tiniakos G, Theodorakis GN, Katritsis DG, Toutouzas PK. Myocarditis in β-thalassemia major-a cause of heart failure. Circulation 1995;91:66-71.
4. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115(5):343-349.
5. McLaughlin VV, Genthner DE, Panella MM, Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998;338:273-277.
6. Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994;121:409-415.
7. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334:296-301.
8. McLaughlin VV, Shillington A, Rich S. Survival of primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002;106(12):1477-1482.
9. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002;40(4):780-788.
10. McLaughlin W, Genthner DE, Panella MM, Hess DM, Rich S. Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series. Ann Intern Med 1999;130:740-743.
11. Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999;99:1858-1865.
12. Humbert M, Sanchez O, Fartoukh M, Jagot JL, et al. Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study. Eur Respir J 1999;13:1351-1356.
13. Krowka MJ, Frantz RP, McGoon MD, Severson C, Plevak DJ, Wiesner RH. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): a study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology 1999;30:641-648.
14. Du ZD, Roguin N, Milgram E, Saab K, Koren A. Pulmonary hypertension in patients with thalassemia major. Am Heart J 1997;134:532-537.
15. Derchi G, Fonti A, Forni GL, Cappellini MD, Turati F. Pulmonary hypertension in patients with thalassemia major [letters to the editor]. Am Heart J 1999;138:384.
16. Aessopos A, Stamatekis G, Skoumas V, Vassilopoulos G, Mantzourani M, Loukopoulos D. Pulmonary hypertension and right heart failure in patients with β-thalassemia intermedia. Chest 1995;107:50-53.
17. 2+ channels in pulmonary arterial smooth muscle cells: a novel mechanism of hypoxic pulmonary hypertension. Circ Res 2004;95:496-505.
18. 2+ entry in agonist-induced pulmonary vasoconstriction. Am J Physiol Lung Cell Mol Physiol 2001;280:L870-L880.
19. Vichinsky EP. Pulmonary hypertension in sickle cell disease. N Engl J Med 2004;350:857-859.
20. Olivieri NF. The β-thalassemias. N Engl J Med 1999;341:99-109.
21. Buja LM, Roberts WC. Iron in the heart: etiology and clinical significance. Am J Med 1971;51:209-221.
22. Kremastinos DT, Tsiapras D, Tsetsos G, Rentoukas E, Vretou H, Toutouzas P. Left ventricular diastolic Doppler characteristics in β-thalassemia major. Circulation 1993;88:1127-1135.
23. Witzleben CL, Wyat JP. The effect of low term survival on the pathology of thalassemia major. J Pathol Bacteriol 1961;82:1-12.
24. Zakynthinos E. Pulmonary hypertension, interstitial lung fibrosis, and lung iron deposition in thalassaemia major. Thorax 2001;56:737-739.
25. Luyt DK, Richards GA, Roode H, Dowdeswell RJ, Van Rensburg AJ, Reinach SG. Thalassemia: Lung transfusion with respect to iron studies and reactive oxidant status. Pediatr Hematol Oncol 1993;10:13-23.
26. Kanj N, Shamseddine A, Gharzeddine W, et al. Relation of ferritin levels to pulmonary function in patients with thalassemia major and the acute effects of transfusion. Eur J Haematol 2000;64:396-400.
27. Mandell MS, Groves BM. Pulmonary hypertension in chronic liver disease. Clin Chest Med 1996;17:17.
28. Lee SL, Wang WW, Lanzillo JJ, et al. Serotonin produces both hyperplasia and hypertrophy of bovine pulmonary artery smooth muscle cells in culture. Am J Physiol 1994;266:L46-L52.
29. Zhan Q, Guo J, Tang J, et al. Alternation of the level of plasma calcitonin gene related peptide and endothelin-1 in liver cirrhosis. Zhonghua Nei Ke Za Zhi 1999;38:91-93.
30. Shah V, Toruner M, Haddad F, et al. Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the rat. Gastroenterology 1999;117:1222-1228.
31. Duke M, Abelmann WH. The hemodynamic response to chronic anemia. Circulation 1969;34:503-515.
32. Olschewski H, Seeger W. Pulmonary hypertension: Pathophysiology, diagnosis, treatment, and development of a pulmonary-selective therapy. Bremen, Germany: UNI-MED Verlag AS: 2002; p 27-38.
33. Nakchbandi IA, Wirth JA, Inzucchi SE. Pulmonary hypertension caused by Graves' thyrotoxicosis: normal pulmonary hemodynamics restored by 1-131 treatment. Chest 1999;116:1483-1485.
34. Bhatia S, Morrison JF, Bower TC, McGoon MD. Pulmonary hypertension in the setting of acquired systemic arteriovenous fistulas. Mayo Clin Procs 2003;78:908-912.
35. Sonakul D, Pacharee P, Laohapand T, Fucharoen S, Wasi P. Pulmonary artery obstruction in thalassemia. Southeast Asian J Trop Med Public Health 1980;11:516-523.
36. Hoeper MM, Niedermeyer J, Hoffmeyer F, Flemming P, Fabel H. Pulmonary hypertension after splenectomy? Ann Intern Med 1999;130:506-509.
37. Heller A, Ragaller M, Schmeck J, et al. Role of NO and endothelin in hemoglobin-induced pulmonary vasoconstriction. Shock 1998;10:401-406.
38. Lin G, Macdonald RL, Marton LS, Kowlalczuk A, Solenski NG, Weir BK. Hemoglobin increases endothelin-1 in endothelial cells by decreasing nitric oxide. Biochem Biophys Res Commun 2001;280:824-830.
39. Reiter CD, Wang X, Tanus-Santos JE, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med 2002;8:1383-1389.
40. Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004;350:886-895.
41. Geraci MW, Gao B, Shepherd DC, et al. Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension. J Clin Invest 1999;103:1509-1515.
42. Hara S, Morishita R, Tone Y, et al. Overexpression of prostacyclin synthase inhibits growth of vascular smooth muscle cells. Biochem Biophys Res Commun 1995;216:862-867.
43. Ramsay MA, Schmidt A, Hein HA, et al. Nitric oxide does not reverse pulmonary hypertension associated with end-stage liver disease: a preliminary report. Hepatology 1997;25:524-527.
44. Findlay JY, Harrison BA, Plevak DJ, Krowka MJ. Inhaled nitric oxide reduces pulmonary artery pressures in portopulmonary hypertension. Liver Transpl Surg 1999;5:381-387.
45. Deem S, Kim JU, Manjula BN, et al. Effects of S-nitrosation and cross-linking of hemoglobin on hypoxic pulmonary vasoconstriction in isolated rat lungs. Circ Res 2002;91:626-632.
46. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994;331:567-573.
47. Wolfe L, Olivieri N, Sallan D, et al. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. N Engl J Med 1985;312:1600-1603.